Conversations in Drug Development Trends
MARCH 7, 2024
Are there differential financial incentives to encourage sponsors to initiate early phase clinical research under a CTA, and how do those incentives compare to incentives that exist to initiate the same research under an IND? For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.
The Pharma Data
SEPTEMBER 11, 2020
“The ability to deliver remdesivir via a long-acting, subcutaneous injection has the potential to expand its application in countries with less developed healthcare systems and help improve patient convenience,” Fairley added. Covid-19 command center aims to accelerate clinical research by individual sponsors to combat disease.
PPD
JUNE 17, 2024
Our PPD FSP solutions help biotech and biopharmaceutical companies meet their timelines by providing top-tier functional expertise that complements existing capabilities and helps companies tackle their unique clinical development challenges.
Expert insights. Personalized for you.
52 
Let's personalize your content